Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
September 24 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a
fireside chat including members of its executive management team
will be broadcast as part of the Cantor Global Healthcare
Conference at 10:00 am ET on Wednesday, September 29, 2021.
To access the webcast of the discussion, please
click here. An archived webcast of the discussion will be available
for 90 days on the Events and Presentations section of Catalyst’s
website.
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a subcutaneously
(SQ) administered next-generation engineered coagulation Factor
VIIa (FVIIa) for the treatment of episodic bleeding in subjects
with rare bleeding disorders. Our complement pipeline includes a
preclinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration, an improved complement factor I
protease for SQ replacement therapy in patients with CFI deficiency
and proteases from our ProTUNE™ C3b-C4b degrader and ImmunoTUNE™
C3a-C5a degrader platforms designed to target specific disorders of
the complement or inflammatory pathways as well as other complement
programs in development.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Forward-looking
statements include, without limitation, statements about the
potential benefits and uses of Catalyst’s product candidates and
the potential benefits of its protease engineering platform and
Catalyst's collaboration with Biogen for the development and
commercialization of a preclinical C3 degrader program for dry
age-related macular degeneration.
Actual results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially, including, but not
limited to, the risk that trials and studies may be delayed as a
result of COVID-19, competitive products and other factors, that
trials may not have satisfactory outcomes; the risks that
Catalyst’s complement degraders have not yet started human clinical
trials; the risk Catalyst may elect to terminate or postpone
ongoing development programs, including development of MarzAA or
any of Catalyst’s complement assets; the risk that costs required
to develop or manufacture Catalyst’s products will be higher than
anticipated, including as a result of delays in trial enrollment,
development and manufacturing resulting from COVID-19 and other
factors; the risk that Catalyst will need to raise additional
capital, which may not be available on favorable terms if at all;
the risk that Biogen may terminate Catalyst's agreement, and other
risks described in the "Risk Factors" section of Catalyst's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (the “SEC”) on March 4, 2021, the Quarterly
Report on Form 10-Q filed with the SEC on August 5, 2021 and in
other filings filed from time to time with the SEC. Catalyst
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024